Practice-entering research
NICHE-2 — neoadjuvant nivolumab + ipilimumab in locally advanced dMMR colon cancer
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE)
- Phase
- Phase II
- Recruitment
- Recruiting
- Results maturity
- Primary analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT03026140
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Short immunotherapy before surgery may shrink some colon cancers. The parent trial still has open cohorts.
Why promising? Very high pathological response rates with neoadjuvant IO in locally advanced dMMR colon cancer.
What is not proven? Randomized phase III superiority; same strategy in pMMR; universal organ-preservation protocol.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NICHE-2: n=111 efficacy; pCR 68%; major response 95%; NEJM 2024. Longer DFS/OS updates in Lancet stream — clinician verification.
Cancer / population: Colon — Metastazsız lokal ileri dMMR kolon
Intervention: Neoadjuvan nivo + ipi → cerrahi
Primary endpoint: Güvenlik (zamanında cerrahi) ve 3y DFS (NICHE-2)
Source-verified summary: Path response 98%; major 95%; pCR 68% (NEJM 2024).
Limitations: Tek kollu; ana NCT altında birden fazla kohort (karıştırma).
Landmark Atlas links
Cross-links are informational only; this module does not award or change gold stars.